These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 34627196)

  • 1. The role of pre-treatment and mid-treatment 18F-FDG PET/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS).
    Zhang Y; Wang G; Zhao X; Hu Y; Tan Su Yin E; Chen D; Wang H; Zhao K
    BMC Med Imaging; 2021 Oct; 21(1):145. PubMed ID: 34627196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
    Wu LL; Liang JH; Wang L; Xu W; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
    [No Abstract]   [Full Text] [Related]  

  • 3. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
    Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Values of Baseline
    Zhou Y; Zhang X; Qin H; Zhao Z; Li J; Zhang B; Sang S; Wu Y; Deng S
    Biomed Res Int; 2020; 2020():9746716. PubMed ID: 32185229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [
    Sachpekidis C; Enqvist O; Ulén J; Kopp-Schneider A; Pan L; Mai EK; Hajiyianni M; Merz M; Raab MS; Jauch A; Goldschmidt H; Edenbrandt L; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2293-2307. PubMed ID: 38456971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma.
    Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F
    Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic role of baseline
    Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
    Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL).
    Cottereau AS; Becker S; Broussais F; Casasnovas O; Kanoun S; Roques M; Charrier N; Bertrand S; Delarue R; Bonnet C; Hustinx R; Gaulard P; de Leval L; Vera P; Itti E; Mounier N; Haioun C; Tilly H; Meignan M
    Ann Oncol; 2016 Apr; 27(4):719-24. PubMed ID: 26787236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [
    Gui J; Li M; Xu J; Zhang X; Mei H; Lan X
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2308-2319. PubMed ID: 38467921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma.
    Albano D; Bosio G; Bianchetti N; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
    Ann Nucl Med; 2019 Jul; 33(7):449-458. PubMed ID: 30929200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
    Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of 18F-FDG lesion dissemination features in patients with peripheral T-cell lymphoma (PTCL).
    Xie Y; Teng Y; Jiang C; Ding C; Zhou Z
    Jpn J Radiol; 2023 Jul; 41(7):777-786. PubMed ID: 36752954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of pretreatment 18F-FDG PET/CT in prognosis and the reflection of tumor burden: a study in pediatric patients with newly diagnosed neuroblastoma.
    Man S; Yan J; Li J; Cao Y; Hu J; Ma W; Liu J; Zhao Q
    Int J Med Sci; 2021; 18(8):1857-1865. PubMed ID: 33746603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic values of baseline, interim and end-of therapy
    Zhou Y; Zhao Z; Li J; Zhang B; Sang S; Wu Y; Deng S
    Cancer Manag Res; 2019; 11():6871-6885. PubMed ID: 31413633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.